Novel Therapeutic Approach Targeting CXCR3 to Treat Immunotherapy Myocarditis
Circulation Research · 28.02.2025 · 136 (5) · 473-490
DOI: 10.1161/circresaha.124.325652 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation Research, erschienen am 28.02.2025. Verfasst von Yuhsin Vivian Huang und 19 weiteren Autor:innen. Beteiligte Einrichtung: Stanford Cardiovascular Institute, CA (Y.V.H., Y.S., H.C., N.W., M.R.V., B.X., Z.L., C.B., R.M.W., P.K.N., S.M.W., H.Z.). Hauptthemen laut MEDLINE: Myocarditis, Receptors, CXCR3, Immunotherapy, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
BACKGROUND: Immune checkpoint inhibitors (ICIs) are successful in treating many cancers but may cause immune-related adverse events. ICI-mediated myocarditis has a high fatality rate with severe cardiovascular consequences. Targeted therapies for ICI myocarditis are currently limited. METHODS: We used a genetic mouse model of PD1 deletion ( MRL/Pdcd1 −/− ) along with a novel drug-treated ICI myocarditis mouse model to recapitulate the disease phenotype. We performed single-cell RNA-sequencing, single-cell T-cell receptor sequencing, and cellular indexing of transcriptomes and epitopes on immune cells isolated from MRL and MRL/Pdcd1 −/− mice at serial time points. We assessed the impact of macrophage deletion in MRL/Pdcd1 −/− mice, then inhibited CXCR3 (C-X-C motif chemokine receptor 3) in ICI-treated mice to assess the therapeutic effect on myocarditis phenotype. Furthermore, we delineated the functional and mechanistic effects of CXCR3 blockade on T-cell and macrophage interactions. We then correlated the results in human single-cell multiomics data from blood and heart biopsy data from patients with ICI myocarditis. RESULTS: Single-cell multiomics demonstrated expansion of CXCL (C-X-C motif chemokine ligand) 9/10+CCR2+ macrophages and CXCR3hi (C-X-C motif chemokine receptor 3 high-expressing) CD8+ (cluster of differentiation) effector T lymphocytes in the hearts of MRL/Pdcd1 −/− mice correlating with onset of myocarditis development. Both depletion of CXCL9/10+CCR2+ (C-C motif chemokine receptor) macrophages and CXCR3 blockade, respectively, led to decreased CXCR3hi CD8+ T-cell infiltration into the heart and significantly improved survival. Transwell migration assays demonstrated that the selective blockade of CXCR3 and its ligand, CXCL10, reduced CXCR3+CD8+ T-cell migration toward macrophages, implicating this interaction in T-cell cardiotropism toward cardiac macrophages. Furthermore, cardiomyocyte apoptosis was induced by CXCR3hi CD8+ T cells. Cardiac biopsies from patients with confirmed ICI myocarditis demonstrated infiltrating CXCR3+ T cells and CXCL9+/CXCL10+ macrophages. Both mouse cardiac immune cells and patient peripheral blood immune cells revealed expanded TCRs (T-cell receptors) correlating with CXCR3hi CD8+ T cells in ICI myocarditis samples. CONCLUSIONS: These findings bring forth the CXCR3-CXCL9/10 axis as an attractive therapeutic target for ICI myocarditis treatment, and more broadly as a druggable pathway in cardiac inflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Stanford Cardiovascular Institute, CA (Y.V.H., Y.S., H.C., N.W., M.R.V., B.X., Z.L., C.B., R.M.W., P.K.N., S.M.W., H.Z.).
- Tufts University School of Medicine, Boston, MA (A.L.B., P.A.).
- F. Edward Hebert School of Medicine at Uniformed Services University, Bethesda, MD (D.L.).
- Division of Cardiovascular Medicine, Stanford, CA (S.W., R.M.W., P.K.N., S.M.W., H.Z.).
- Massachusetts General Hospital Cancer Center, Boston, MA (S.W.).
- Division of Oncology, Stanford, CA (J.W.N., H.A.W.).
ORCID-Profile: Yuhsin Vivian Huang, Yin Sun, Noah Wagner, Abraham L Bayer, Zachary Lin, Joel W Neal, Heather A Wakelee, Ronald M Witteles, Patricia K Nguyen, Edward E Graves, Gerald J Berry, Pilar Alcaide, Sean M Wu, Han Zhu
Förderung
- NHLBI NIH HHS
Zitieren
APA
Huang, Y. V., Sun, Y., Chou, H., Wagner, N., Vitale, M. R., Bayer, A. L., Xu, B., Lee, D., Lin, Z., Branche, C., Waliany, S., Neal, J. W., Wakelee, H. A., Witteles, R. M., Nguyen, P. K., Graves, E. E., Berry, G. J., Alcaide, P., Wu, S. M., & Zhu, H. (2025). Novel Therapeutic Approach Targeting CXCR3 to Treat Immunotherapy Myocarditis. Circulation Research, 136(5), 473-490. https://doi.org/10.1161/circresaha.124.325652
Vancouver
Huang YV, Sun Y, Chou H, Wagner N, Vitale MR, Bayer AL, et al. Novel Therapeutic Approach Targeting CXCR3 to Treat Immunotherapy Myocarditis. Circulation Research. 2025;136(5):473-490. doi:10.1161/circresaha.124.325652
BibTeX
@article{Huang2025,
author = {Huang, Yuhsin Vivian and Sun, Yin and Chou, Harrison and Wagner, Noah and Vitale, Maria Rosaria and Bayer, Abraham L and Xu, Bruce and Lee, Daniel and Lin, Zachary and Branche, Corynn and Waliany, Sarah and Neal, Joel W and Wakelee, Heather A and Witteles, Ronald M and Nguyen, Patricia K and Graves, Edward E and Berry, Gerald J and Alcaide, Pilar and Wu, Sean M and Zhu, Han},
title = {Novel Therapeutic Approach Targeting CXCR3 to Treat Immunotherapy Myocarditis},
journal = {Circulation Research},
year = {2025},
volume = {136},
number = {5},
pages = {473--490},
doi = {10.1161/circresaha.124.325652}
}
EUVIMED